Loading...
•
Jun 30, 2021
Astrana Health Q2 2021 Earnings Report
Announced second quarter 2021 results, showing revenue increase and raised full-year guidance.
Key Takeaways
Apollo Medical Holdings reported a 6% increase in revenue to $175.6 million and an 80% increase in net income attributable to ApolloMed to $12.7 million for the second quarter of 2021. The company also raised its full-year 2021 guidance due to continued organic growth and encouraging results in the first half of the year.
Q2 earnings per share - diluted (“EPS - diluted”) of $0.28 per share, up 47% from the prior-year quarter
Q2 total revenue of $175.6 million, up 6% from the prior-year quarter
Q2 net income attributable to ApolloMed of $12.7 million, up 80% from the prior-year quarter
ApolloMed completed the successful refinancing of its existing term loan and revolving credit facility with a new five-year revolving credit facility of $400.0 million
Revenue by Segment
Forward Guidance
ApolloMed is raising its full-year 2021 guidance as a result of continued organic growth and encouraging results in the first half of the year.
Positive Outlook
- Total revenue is expected to be between $700 million and $720 million.
- Net income is expected to be between $56 million and $66 million.
- Net income attributable to ApolloMed is expected to be between $48 million and $58 million.
- EBITDA is expected to be between $100 million and $119 million.
- Adjusted EBITDA is expected to be between $120.5 million and $130.5 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...